MONUMENT ADVOCACY
MONUMENT ADVOCACY filed a Q2 report for NOVARTIS on July 20, 2026, reporting $60,000 in lobbying income.
Lobbying for NOVARTIS · Vaccine and diagnostic manufacturing
Issues related to domestic healthcare and pricing; Issues related to cell, gene therapies, and radioligand therapies; Issues related to supply chain management, issues related to intellectual property; issues related to tariffs; issues related to ESRD; Most Favored Nation drug pricing policy
Issues related to ongoing trade negotiations; Issues related to US/China relations; Issues related to international intellectual property; Issues related to global health; issues related to supply chain; and issues related to tariffs, issues related to ESRD.
Issues related to US and international tax provisions; issues related to ESRD